{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:22:08Z","timestamp":1788175328994,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-030331"],"award-info":[{"award-number":["POCI-01-0145-FEDER-030331"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.10043.BD"],"award-info":[{"award-number":["2020.10043.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0058\/2020"],"award-info":[{"award-number":["LA\/P\/0058\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04539\/2020"],"award-info":[{"award-number":["UIDP\/04539\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020"],"award-info":[{"award-number":["UIDB\/04539\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/139142\/2018"],"award-info":[{"award-number":["SFRH\/BD\/139142\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00e1tico Factores de Competitividade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115209","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:28:40Z","timestamp":1786033720000},"page":"115209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u03b2-glucan particles as oral carriers for a dual-antigen hepatitis B vaccine: Liver targeting and immune potentiation following subcutaneous priming"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-8945","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Pan\u00e3o-Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5147-7226","authenticated-orcid":false,"given":"Mariana","family":"Cola\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7032-9599","authenticated-orcid":false,"given":"Paulo","family":"F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra A.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia M.F.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-5121","authenticated-orcid":false,"given":"Olga","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115209_b0005","unstructured":"World Health Organization. Global Hepatitis Report 2026. Geneva: World Health Organization; 2026. Available from: https:\/\/iris.who.int\/items\/b89fc26c-9fdb-465a-ae3d-a325a35bd4e7."},{"key":"10.1016\/j.ejpb.2026.115209_b0010","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17474124.2023.2268503","article-title":"A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments","volume":"17","author":"Laupeze","year":"2023","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2026.115209_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051114","article-title":"CD4(+) T Cells in chronic hepatitis B and T cell-directed immunotherapy","volume":"10","author":"Buschow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2026.115209_b0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2026.115209_b0030","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2015.03.079","article-title":"Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115209_b0035","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2026.115209_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2019.02.006","article-title":"Innate sensors that regulate vaccine responses","volume":"59","author":"Georg","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2014.07.015","article-title":"Immunizations with hepatitis B viral antigens and a TLR7\/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice","volume":"29","author":"Wang","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2026.115209_b0050","article-title":"Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.115209_b0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11095-009-0011-3","article-title":"Mucosal vaccines: recent progress in understanding the natural barriers","volume":"27","author":"Borges","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115209_b0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s11095-010-0314-4","article-title":"Progress towards a needle-free hepatitis B vaccine","volume":"28","author":"Lebre","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115209_b0065","first-page":"1971","article-title":"Glucan particles are a powerful adjuvant for the HBsAg","volume":"16","author":"Soares","year":"2019","journal-title":"Favoring Antiviral Immunity. Mol Pharm"},{"key":"10.1016\/j.ejpb.2026.115209_b0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1021\/bc700329p","article-title":"Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery","volume":"19","author":"Soto","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2026.115209_b0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jconrel.2013.09.007","article-title":"beta-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination","volume":"172","author":"De Smet","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115209_b0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2017.11.009","article-title":"Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming","volume":"535","author":"Soares","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115209_b0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijpharm.2016.03.013","article-title":"Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-epsilon-caprolactone based nanoparticles","volume":"504","author":"Jesus","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115209_b0090","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.ijbiomac.2018.08.019","article-title":"In vitro anti-Leishmania activity of T6 synthetic compound encapsulated in yeast-derived \u03b2-(1,3)-d-glucan particles","volume":"119","author":"Volpato","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2026.115209_b0095","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/pharmaceutics17081032","article-title":"Yeast-derived glucan particles: biocompatibility, efficacy, and immunomodulatory potential as adjuvants and delivery systems","volume":"17","author":"Pan\u00e3o-Costa","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115209_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127078","article-title":"Exploring TLR agonists as adjuvants for COVID-19 oral vaccines","volume":"53","author":"F\u00e9lix","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115209_b0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1567201814666170825153955","article-title":"Oral vaccination through Peyer's patches: update on particle uptake","volume":"15","author":"Soares","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115209_b0110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.28166","article-title":"Recent advances in oral vaccine development: yeast-derived beta-glucan particles","volume":"10","author":"De Smet","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ejpb.2026.115209_b0115","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1039\/C5NR07474F","article-title":"Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery","volume":"8","author":"Hu","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2026.115209_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2013.11.028","article-title":"Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study","volume":"460","author":"Niu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115209_b0125","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1039\/C5TB02706C","article-title":"Tracking translocation of glucan microparticles targeting M cells: implications for oral drug delivery","volume":"4","author":"Xie","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejpb.2026.115209_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6446(05)03536-1","article-title":"Intestinal Peyer\u2019s patch M cells and oral vaccine targeting","volume":"10","author":"Brayden","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2026.115209_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117258","article-title":"Beta-d-glucan-based drug delivery system and its potential application in targeting tumor associated macrophages","volume":"253","author":"Su","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2026.115209_b0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0939-6411(00)00084-9","article-title":"Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?","volume":"50","author":"Jung","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115209_b0145","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/acs.nanolett.6b04523","article-title":"Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route","volume":"17","author":"Zhou","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2026.115209_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-374530-9.00012-7","article-title":"Lymphocyte trafficking","volume":"449\u2013482","author":"Kogan","year":"2008","journal-title":"Microcirculation"},{"key":"10.1016\/j.ejpb.2026.115209_b0155","doi-asserted-by":"crossref","first-page":"G473","DOI":"10.1152\/ajpgi.00271.2021","article-title":"Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension","volume":"322","author":"Juneja","year":"2022","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejpb.2026.115209_b0160","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.21037\/atm-22-5299","article-title":"Novel albendazole-glucan particles for enhancing intestinal absorption and improving hepatic targeting","volume":"10","author":"Liu","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejpb.2026.115209_b0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1053\/jhep.2001.27218","article-title":"Low-molecular-weight hyaluronic acid induces nuclear factor-kappaB-dependent resistance against tumor necrosis factor alpha-mediated liver injury in mice","volume":"34","author":"Wolf","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejpb.2026.115209_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrgentox.2014.09.005","article-title":"Effects of barley beta-glucan on radiation damage in the human hepatoma cell line HepG2","volume":"775\u2013776","author":"Ghavami","year":"2014","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.ejpb.2026.115209_b0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jff.2017.12.045","article-title":"Oat \u03b2-glucan inhibits adipogenesis and hepatic steatosis in high fat diet-induced hyperlipidemic mice via AMPK signaling","volume":"41","author":"Liu","year":"2018","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.ejpb.2026.115209_b0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijbiomac.2013.03.040","article-title":"Cytotoxic effect of Agaricus bisporus and Lactarius rufus beta-D-glucans on HepG2 cells","volume":"58","author":"Pires Ado","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2026.115209_b0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.etp.2008.05.003","article-title":"Protective effects of beta-glucan extracted from barley against benzo[a]pyrene-induced DNA damage in hepatic cell HepG2","volume":"61","author":"Angeli","year":"2009","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2026.115209_b0195","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1021\/acs.chemrev.8b00626","article-title":"Reactive oxygen species (ROS)-based nanomedicine","volume":"119","author":"Yang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2026.115209_b0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2015.10.025","article-title":"beta-glucan microparticles targeted to epithelial APN as oral antigen delivery system","volume":"220","author":"Baert","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115209_b0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fimmu.2017.00791","article-title":"beta-glucan size controls dectin-1-mediated immune responses in human dendritic cells by regulating IL-1beta production","volume":"8","author":"Elder","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0210","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.vaccine.2023.04.063","article-title":"Endotoxin contamination of nanoparticle formulations: A concern in vaccine adjuvant mechanistic studies","volume":"41","author":"Panao Costa","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115209_b0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2026.115209_b0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/ni.1692","article-title":"Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk","volume":"10","author":"Gringhuis","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.humimm.2015.01.009","article-title":"beta-Glucan enhances cytotoxic T lymphocyte responses by activation of human monocyte-derived dendritic cells via the PI3K\/AKT pathway","volume":"76","author":"Ding","year":"2015","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0230","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cellimm.2015.10.007","article-title":"Microparticulate beta-glucan vaccine conjugates phagocytized by dendritic cells activate both naive CD4 and CD8 T cells in vitro","volume":"298","author":"Berner","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0235","doi-asserted-by":"crossref","unstructured":"H. Huang, G. R. Ostroff, C. K. Lee, C. A. Specht, S. M. Levitz, Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. mBio 1, doi:10.1128\/mBio.00164-10 (2010).","DOI":"10.1128\/mBio.00164-10"},{"key":"10.1016\/j.ejpb.2026.115209_b0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1132742","article-title":"Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells","volume":"314","author":"Mora","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2026.115209_b0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cellimm.2007.07.004","article-title":"Granzyme B production distinguishes recently activated CD8+ memory cells from resting memory cells","volume":"247","author":"Nowacki","year":"2007","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1600-065X.2003.00044.x","article-title":"Granzyme B: a natural born killer","volume":"193","author":"Lord","year":"2003","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejpb.2026.115209_b0255","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1016\/j.vaccine.2010.06.117","article-title":"TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity","volume":"28","author":"Du","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115209_b0260","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0265","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/vim.2014.0022","article-title":"Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption","volume":"27","author":"Chokshi","year":"2014","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-019-0309-9","article-title":"CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B","volume":"20","author":"Dong","year":"2019","journal-title":"BMC Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.805625","article-title":"Cytokines and Chemokines in HBV Infection","volume":"8","author":"Zhong","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejpb.2026.115209_b0280","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.antiviral.2012.12.018","article-title":"IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2. 2.15 cell line","volume":"97","author":"Wang","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejpb.2026.115209_b0285","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2008.00703.x","article-title":"Th17 cytokines and mucosal immunity","volume":"226","author":"Dubin","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejpb.2026.115209_b0290","article-title":"IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome","volume":"10","author":"Palumbo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.115209_b0295","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1128\/jvi.66.6.3955-3960.1992","article-title":"Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice","volume":"66","author":"Gilles","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2026.115209_b0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2026.115209_b0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","article-title":"TNF-\u03b1\/IFN-\u03b3 profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection","volume":"72","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2026.115209_b0310","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: signaling mechanisms and biologic functions","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0315","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2012.12.074","article-title":"A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice","volume":"31","author":"Buchmann","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115209_b0320","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/757246","article-title":"Circulating cytokines and histological liver damage in chronic hepatitis B infection","volume":"2013","author":"Poovorawan","year":"2013","journal-title":"Hepatitis research and treatment"},{"key":"10.1016\/j.ejpb.2026.115209_b0325","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1542-3565(05)00404-0","article-title":"Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study","volume":"3","author":"Weng","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2026.115209_b0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2026.115209_b0335","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"Michel","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2026.115209_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151595","article-title":"Dual functionalization of chitosan\/DNA complexes with mannose and hydroxyl-rich acids for enhanced gene delivery efficiency","author":"Cola\u00e7o","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2026.115209_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.147492","article-title":"Optimizing mucosal vaccination: Exploiting Lactobionic acid-modified chitosan for superior gene delivery systems","author":"Cola\u00e7o","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2026.115209_b0350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.115209_b0355","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1751-7915.2011.00303.x","article-title":"Design of therapeutic vaccines: hepatitis B as an example","volume":"5","author":"Kutscher","year":"2012","journal-title":"J. Microbial. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115209_b0360","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ejpb.2026.115209_b0365","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coviro.2021.10.002","article-title":"Immunotherapy and therapeutic vaccines for chronic HBV infection","volume":"51","author":"Lang-Meli","year":"2021","journal-title":"Curr. Opin. Virol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:12:47Z","timestamp":1788174767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"alternative-id":["S0939641126002304"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115209","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-glucan particles as oral carriers for a dual-antigen hepatitis B vaccine: Liver targeting and immune potentiation following subcutaneous priming","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115209"}}